Name

Neogenix Biosciences

Legal name

NeoGenix Biosciences Pty Ltd

Website

https://neogenixbiosciences.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Fertility Medical Devices

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

Keywords

• IVF medical devices
• Sperm selection technology
• AI sperm detection
• Microfluidic fertility devices
• Assisted reproductive technology

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SpermSearch.AI Software: AI-powered software platform sold as a co-pilot tool for embryologists in IVF laboratories. Currently offered through Early Access Program for evaluation.
2. SpermGuide Device: Microfluidic sperm selection device in development. To be commercialized as a medical device for laboratory use in sperm isolation procedures.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Neogenix Biosciences develops and commercializes AI and microfluidic technologies for sperm identification and selection in IVF laboratories. The company's core offerings are SpermSearch.AI, an AI-powered computer vision software co-pilot that identifies sperm forms in real-time during surgical and extended semen searches, and SpermGuide, a microfluidic device that passively isolates highly-motile sperm with low DNA fragmentation using biomimetic channel geometries. Both products target enterprise IVF clinics globally and are validated through peer-reviewed clinical studies and partnerships with leading fertility centers.

Product overview

Neogenix Biosciences is an Australian med-tech company developing a portfolio of two complementary AI and microfluidic technologies for sperm identification and selection in IVF. The core offerings are SpermSearch.AI, an AI-powered computer vision co-pilot that identifies and localizes sperm forms in real-time during surgical and semen extended sperm searches, and SpermGuide, a microfluidic sperm selection device that passively isolates motile sperm with low DNA fragmentation through biomimetic channel geometries. Together, these technologies address the key bottlenecks in IVF fertility care: accelerating sperm detection in severe male-factor cases and improving sperm quality for fertilization.

Differentiator

Problem solved

Functional benefit

Brands

• SpermGuide: A microfluidic, channel-based device that passively selects highly-motile sperm with low DNA fragmentation using biomimetic geometries without centrifugation.
• SpermSearch.AI

Products and services

• SpermSearch.AI

Quantifiable outcome

• Significantly better at lowering DNA fragmentation index (DFI) than density gradient centrifugation (DGC) in both research (P = 0.012) and clinical cohorts (P < 0.001)
• +4 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Four partnerships are on record, tiered minor and core.

• AMA (Australian Medical Association)minorStrategic or Co-development PartnerListed as a collaborator on the company website, indicating research or development partnership in the reproductive medicine space.
• University of Technology Sydney (UTS)minorStrategic or Co-development PartnerListed as a collaborator indicating academic research partnership in microfluidics and medical technology development.
• UNSW AustraliaminorStrategic or Co-development PartnerListed as a collaborator with research expertise in microfluidics and reproductive technology development. Multiple co-authors from UNSW on published papers.
• IVF AustraliacoreStrategic or Co-development PartnerClinical partner contributing real-world data to NeoGenix. Presented clinical results at ESHRE 2025 including pregnancies and a live birth enabled by SpermSearch.AI. Active collaboration for clinical validation studies.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Genea Biomedx: Australian IVF medical-device company (subsidiary of Genea) developing lab instruments and consumables for ART clinics, including sperm preparation and embryo culture systems. Most direct geographic and product overlap with NeoGenix's SpermGuide microfluidic and SpermSearch.AI workflows.
• Memphasys: Australian-listed medtech developing the Felix device, a non-centrifugation sperm separation technology for IVF/ICSI. Directly comparable to SpermGuide in target use case (DNA-fragmentation reduction and operator-bias-free sperm selection).
• Hamilton Thorne: Public company (TSX:HTL) selling laser systems, sperm analyzers (CASA), and lab instruments to IVF and animal-breeding markets. Directly comparable in the IVF lab equipment category and a likely competitor for capital and clinic relationships.

Broad incumbents

• Vitrolife: Global Swedish-listed IVF consumables and device company (media, microtools, lab equipment) serving the same IVF clinic buyers. Broad incumbent with the installed base and regulatory reach to bundle or compete with NeoGenix's offerings.
• CooperSurgical: Large US-based women's health and fertility medical-device company with a broad portfolio including IVF media, microtools, and lab equipment. Comparable as a broad incumbent with established IVF clinic relationships NeoGenix must sell into.
• FUJIFILM Irvine Scientific: Major ART media, equipment, and device supplier acquired by Fujifilm. Comparable as a broad incumbent supplying IVF labs with the consumables and instruments that sit alongside NeoGenix's sperm-selection workflow.

Emerging players

• Fairtility: Israeli AI-in-ART company offering CHLOE, an AI embryo-selection platform for IVF labs. Comparable as an AI co-pilot for embryologists in the same clinical workflow, though focused on embryo rather than sperm morphology.
• Mojo Fertility: European AI-in-IVF startup applying computer vision and machine learning to sperm and embryo analysis. Comparable as a peer-stage AI company competing for the same IVF lab computer-vision category.
• ImVitro: French AI-in-ART company offering an IVF decision-support platform that analyzes time-lapse embryo data. Comparable as an early-stage AI co-pilot targeting IVF lab decision workflows.

Others

• Carl Zeiss Microscopy: Microscope manufacturer whose imaging platforms underpin IVF lab workflows and with whom NeoGenix already collaborates via Evident. Relevant as an ecosystem partner/incumbent that could integrate competing AI detection features into its hardware.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NeoGenixBio
• LinkedInlinkedin.com/company/neogenix-biosciences-pty-ltd
• Instagraminstagram.com/neogenixbiosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neogenix Biosciences